Navigation Links
Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Discusses Prostate Cancer Stage vs. Gleason Score
Date:8/27/2013

Oakland, CA (PRWEB) August 27, 2013

Dennis R. Hill M.D. Radiation Oncologist at the Alta Bates Summit Medical Center in Oakland, CA reports that a recently published study confirms his experience that PSA screening has detected prostate cancer at a much earlier stage or tumor size. The journal Cancer Research published August 14, 2013 Abstract looked at 1,207 men who were diagnosed with prostate cancer from 1982 to 2004 and subsequently treated with surgery as their treatment for prostate cancer. They found that the proportion of advanced-stage tumors (=T3) dropped from 19.9% during the earliest period of the study (1982–1993, when PSA screening was not well established) to 3% during the latest period of the study (2000–2004). In other words, the proportion of advanced stage tumors dropped more than six-fold from the pre PSA screening era to the PSA screening era.

On the other hand, they report the proportion of high Gleason scores or the appearance of the cancer cells when viewed under a microscope decreased substantially less. Gleason grade 4 + 4 prostate cancer or greater dropped from 25.3% to 17.6% across the pre-PSA and PSA screening eras. It is unknown whether prostate cancers arise well differentiated and then progress to less differentiated forms. However, this study says that Gleason grade is an early and largely unchanging feature because the expectation is that Gleason grade and clinical stage would progress together. Prostate cancer treatment options take into account both stage and Gleason score.

They conclude, “This has implications for the understanding of tumor progression and prognosis, and may help patients diagnosed with lower grade disease feel more comfortable choosing active surveillance.”

Dr. Hill says, “I know that we have a higher cure rate with a lower stage of disease but this report suggests that there is a group of men with low grade disease that can be safely followed since Gleason grade progression is relatively uncommon.”

About Dennis R. Hill MD

Dr. Hill has been doing High Dose Rate Brachytherapy exclusively since 2004 and has published scholarly articles on the subject. His office is located at: Dennis R. Hill MD 3012 Summit Street Suite 2675 Oakland, CA | 94609 510-869-8875 | drh(at)dennisrhillmd(dot)com and his website is hdrprostatebrachytherapy.com, which includes a quiz to determine if a patient is a candidate for HDR Prostate Brachytherapy.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11061630.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
2. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
3. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same
4. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
5. Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
6. New Online Course Explores Mouse as Model for Prostate Cancer
7. NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI
8. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
9. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
10. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
11. Cost effective prostate cancer treatment underused in the UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
(Date:10/6/2017)... ... 06, 2017 , ... The HealthTech Venture Network (HTVN) is ... fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited to ... showcasing early stage digital health and med tech companies. , This day-long event ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):